Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

STX140, a bis-sulfamate derivative of the endogenous steroid 2-methoxyestradiol, has shown promising anti-cancer potency both in vitro and in vivo, with excellent bioavailability. Its activity against taxane-resistant xenografts make it a potential drug candidate against triple negative breast cancer (TNBC). These properties are linked to the ability of STX140 to act in a multi-targeting fashion in vivo as a microtubule disruptor, leading to cell cycle arrest and with both pro-apoptotic and anti-angiogenic activities. Carbonic Anhydrase IX (CA IX) is a well-established biomarker for aggressive cancers, including TNBC. This study reports, for the first-time, the inhibitory activities of a series of steroidal and non-steroidal sulfamate derivatives against CA IX in comparison to the ubiquitous CA II, with some compounds demonstrating 100-200 fold selectivity for CA IX over CA II. X-ray crystallographic studies of four of the most promising compounds reveal isoform specific residue interactions responsible for the high specificity.

Original publication




Journal article


J Med Chem

Publication Date